Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds

Funded Grants

Back to results

Elatus: Chronically Implantable Unit-Scale Microelectrode Array Neuromodulation Technology

Project Overview

Challenge: Current DRE standard of care is either DBS (Medtronic, Boston Scientific), Vagus Nerve Stimulation (VNS – Livanova) or Responsive Nerve Stimulation (RNS – NeuroPace). These devices rarely eliminate seizures, and there is little to differentiate them from one another. Typically, median seizure reduction is 50-70% which, while statistically significant, does little to appreciably improve the patient’s quality of life. Patients still need to live with the day-to-day spectre of seizures, they cannot regain their drivers’ licence, they cannot independently care for children, or perform any other activities of daily living that present even mild inherent physical risk (bike riding, climbing a ladder, swimming etc.).

Solution: “”Elatus”” is a chronically implantable neuron-scale multi-electrode cortical array for the treatment of drug-refractory neurological conditions, beginning with DRE. Unlike low-resolution iEEG, our array uses unit-level spike data to measure brain criticality, which correlates with seizure probability. The electrode technology is derived from years of materials science research at the University of Melbourne. This is coupled with integrated circuits the team at the Université de Sherbrooke is designing to analyse these spiking waveforms and safely transmit this data to external systems. This capability means Elatus can provide much more “actionable” data to clinicians to inform patient therapies and more quickly and completely reduce seizure events. Ultimately Elatus will use criticality data to more effectively apply a closed loop electrical therapy, eliminating seizures far more effectively than current EEG-based closed-loop systems.

Expected Achievements/Impact: Patients with Elatus will be able to resume their normal lives, in most cases seizure-free. They will be able to re-claim their jobs, their ability to drive, their confidence in various activities, and cease to be a medical/social/financial burden to their families and society. Carbon Cybernetics will grow commercially because of this funding, providing high quality STEM jobs to the province of Québec.

Principal Investigator

Réjean Fontaine , Université de Sherbrooke

Team Members

Christian Iorio-Morin, Université de Sherbrooke

Ana Suller-Marti, Western University

Walter Hader, University of Calgary

Partners and Donors

CQDM

Carbon Cybernetics

Project Ongoing

Elatus: Chronically Implantable Unit-Scale Microelectrode Array Neuromodulation Technology

  • Area of research

    Seizure

  • Disease Area

    Epilepsy

  • Province

    Québec

  • Start Date

    2025

  • Total Grant Amount

    $1,657,750

  • Health Canada Contribution

    $828,875

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Please note all online donations will receive an electronic tax receipt, issued by Brain Canada Foundation.

Our Donors

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2025 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co

  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds
Project Directory
Donate Now